PTC THERAPEUTICS, INC.
PTCTNasdaq
$78.59
↑ +0.1%Jul 17 close · end-of-day
Price
1Y↑ +63.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$6.5B
Enterprise Value
$4.9B
P/E
—
P/S
7.8
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-3.5%
Dividend Yield
—
Revenue (TTM)
$827.1M
Net Income (TTM)
-$186.4M
Free Cash Flow (TTM)
-$226.3M
Gross Margin
—
Operating Margin
-7.0%
Net Margin
-22.5%
ROE
103.3%
ROIC
—
Debt / Equity
-1.6
Net Cash
$1.6B
Return 1Y
+61.9%
Company profile
PTC Therapeutics focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States; Tegsedi and Waylivra for the. treatment of rare diseases in Latin America and the Caribbean. PTC518 is being developed for Huntington's disease.
- CEO
- Stuart W. Peltz
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 1,410
- Headquarters
- New Jersey
- Website
- ptcbio.com
Management & directors
- Gravier PierreCHIEF FINANCIAL OFFICER
- Almstead Neil GregoryCHIEF TECHNICAL OPS OFFICER
- Boulding Mark ElliottEXEC. VP AND CLO
- Utter Christine MarieSVP, CHIEF ACCOUNTING OFFICER
- Pauwels EricCHIEF BUSINESS OFFICER
- Klein Matthew B.CHIEF EXECUTIVE OFFICER
- Golden Lee ScottEVP & CHIEF MEDICAL OFFICER
Roles derived from SEC Form 4 filings.
Earnings
PTCT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$272.6M↓ -76.8%
Diluted EPS-$0.03↓ -100.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $380.8M | $538.6M | $698.8M | $937.8M | $806.8M | $1.7B |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$431.8M | -$374.4M | -$447.4M | -$439.5M | -$302.6M | $866.9M |
| Net income | -$438.2M | -$523.9M | -$559.0M | -$626.6M | -$363.3M | $683.0M |
| Diluted EPS | -$6.64 | -$7.43 | -$7.79 | -$8.37 | -$4.73 | $7.78 |
| Operating cash flow | -$194.1M | -$251.3M | -$356.7M | -$158.4M | -$107.7M | $711.2M |
| Free cash flow | -$211.9M | -$279.5M | -$388.7M | -$186.9M | -$114.2M | $702.3M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -113.4% | -69.5% | -64.0% | -46.9% | -37.5% | 50.1% |
| Net margin | -115.1% | -97.3% | -80.0% | -66.8% | -45.0% | 39.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $186.7M | $196.8M | $213.2M | $1.2B | $178.9M | $211.0M | $164.7M | $272.6M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$40.2M | -$54.5M | -$162.4M | $970.2M | -$35.0M | $3.0M | -$71.3M | $45.0M |
| Net income | -$99.2M | -$106.7M | -$65.9M | $866.6M | -$64.8M | $15.9M | -$134.6M | -$2.8M |
| Diluted EPS | -$1.29 | -$1.39 | -$0.85 | $10.04 | -$0.83 | $0.20 | -$1.63 | -$0.03 |
| Operating cash flow | -$71.5M | -$77.0M | -$30.0M | $870.1M | -$58.3M | -$66.3M | -$34.3M | -$59.0M |
| Free cash flow | -$78.8M | -$77.5M | -$33.8M | $868.4M | -$59.6M | -$69.7M | -$36.6M | -$60.2M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -21.5% | -27.7% | -76.2% | 82.5% | -19.5% | 1.4% | -43.3% | 16.5% |
| Net margin | -53.1% | -54.2% | -30.9% | 73.7% | -36.3% | 7.5% | -81.7% | -1.0% |
Company news
Jul 17, 2026
Jul 13, 2026
Jul 11, 2026
Jul 10, 2026
- 9d agoIs PTC Therapeutics (PTCT) A Bargain Following Its Russell 2000 Defensive Index Additions?finance.yahoo.com
- 10d agoImmunome Stock Up 32% in a Month: Here's What You Should Knowfinance.yahoo.com
- 10d agoZacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMNfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-14 | Gravier Pierre· CHIEF FINANCIAL OFFICER | Sale | 3,494 | $80.35 | $280,742.90 | filing |
| 2026-07-09 | Smith Mary L. | Sale | 10,000 | $90.00 | $900,000.00 | filing |
| 2026-07-09 | Smith Mary L. | Sale | 5,834 | $90.00 | $525,060.00 | filing |
| 2026-07-09 | Smith Mary L. | Option exercise | 10,000 | $42.95 | $429,500.00 | filing |
| 2026-07-09 | Smith Mary L. | Option exercise | 5,834 | $42.95 | $250,570.30 | filing |
| 2026-07-09 | Almstead Neil Gregory· CHIEF TECHNICAL OPS OFFICER | Sale | 2,464 | $90.25 | $222,376.00 | filing |
| 2026-07-09 | Almstead Neil Gregory· CHIEF TECHNICAL OPS OFFICER | Option exercise | 2,464 | $46.54 | $114,674.56 | filing |
| 2026-07-07 | Almstead Neil Gregory· CHIEF TECHNICAL OPS OFFICER | Sale | 11,369 | $89.03 | $1.0M | filing |
| 2026-07-07 | Almstead Neil Gregory· CHIEF TECHNICAL OPS OFFICER | Option exercise | 24,613 | $39.42 | $970,244.46 | filing |
| 2026-07-07 | Almstead Neil Gregory· CHIEF TECHNICAL OPS OFFICER | Sale | 9,288 | $89.44 | $830,718.72 | filing |
| 2026-07-07 | Almstead Neil Gregory· CHIEF TECHNICAL OPS OFFICER | Sale | 3,956 | $87.17 | $344,844.52 | filing |
| 2026-07-06 | Almstead Neil Gregory· CHIEF TECHNICAL OPS OFFICER | Sale | 10,090 | $86.32 | $870,968.80 | filing |
| 2026-07-06 | Almstead Neil Gregory· CHIEF TECHNICAL OPS OFFICER | Sale | 8,786 | $85.35 | $749,885.10 | filing |
| 2026-07-06 | Almstead Neil Gregory· CHIEF TECHNICAL OPS OFFICER | Option exercise | 18,876 | $38.10 | $719,175.60 | filing |
| 2026-07-06 | Almstead Neil Gregory· CHIEF TECHNICAL OPS OFFICER | Sale | 2,474 | $87.03 | $215,312.22 | filing |
| 2026-07-06 | Boulding Mark Elliott· EXEC. VP AND CLO | Option exercise | 2,813 | $46.54 | $130,917.02 | filing |
| 2026-07-06 | Almstead Neil Gregory· CHIEF TECHNICAL OPS OFFICER | Option exercise | 2,474 | $39.42 | $97,525.08 | filing |
| 2026-07-06 | Boulding Mark Elliott· EXEC. VP AND CLO | Option exercise | 2,266 | $39.42 | $89,325.72 | filing |
| 2026-07-06 | Boulding Mark Elliott· EXEC. VP AND CLO | Sale | 1,036 | $84.41 | $87,448.76 | filing |
| 2026-07-06 | Boulding Mark Elliott· EXEC. VP AND CLO | Sale | 833 | $84.41 | $70,313.53 | filing |
| 2026-07-06 | Boulding Mark Elliott· EXEC. VP AND CLO | Sale | 745 | $86.38 | $64,353.10 | filing |
| 2026-07-06 | Boulding Mark Elliott· EXEC. VP AND CLO | Sale | 645 | $85.84 | $55,366.80 | filing |
| 2026-07-06 | Boulding Mark Elliott· EXEC. VP AND CLO | Sale | 601 | $86.38 | $51,914.38 | filing |
| 2026-07-06 | Boulding Mark Elliott· EXEC. VP AND CLO | Sale | 519 | $85.84 | $44,550.96 | filing |
| 2026-07-06 | Almstead Neil Gregory· CHIEF TECHNICAL OPS OFFICER | Sale | 426 | $85.28 | $36,329.28 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.